◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral WATCH-LIST LOW

BPAP

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST LOW

Mechanistically the cleanest selegiline successor on paper (pure CAE without MAO inhibition, ~130× more potent in rat models, broader serotonergic coverage) and Knoll's animal lifespan + tumor-suppression data is impressive — but ZERO published human RCTs, only one Phase 2 Parkinson's program by Fujimoto Pharma (status pending/unclear, no public results), and sub-mg dosing demands research-chem identity + COA confidence at a level where dose-error catastrophe is real. Verdict would upgrade to OPTIONAL-ADD with HIGH confidence if a single well-designed human Phase 1 PK/safety study landed; would downgrade to SKIP-FOR-NOW if a credible hepatotoxicity or arrhythmia signal emerges (the benzofuran scaffold has class-level liver concern flagged for benzbromarone/benzarone — not yet shown for BPAP).

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    WATCH-LIST

    / OPTIONAL-WITH-CAVEATS, LOW confidence. Could genuinely replace low-oral selegiline in V5 stack with cleaner mechanism + broader monoamine coverage + (in animal models) better lifespan + cognitive-aging signal. But: human safety/PK unknown, research-chem identity is non-negotiable at sub-mg dosing, the benzofuran liver-class concern is unresolved, and the Fujimoto Phase 2 status is opaque. Recommendation: do NOT add to V5 launch stack. Reconsider as a selegiline-replacement candidate after: (a) Dylan has 6+ months of low-oral selegiline experience as baseline, (b) 23andMe results indicate pharmacogenomic context (DAT, COMT, TAAR1 if available), (c) bloodwork establishes liver baseline. If still interested at that point, single-vendor sourcing (Kimera) + small starter dose (50 mcg/day) + structured 4-week trial with subjective + BP/HR + ALT/AST monitoring would be a defensible experimental approach.

  • 30-50, executive maintenance
    WATCH-LIST

    Same profile as Dylan but with slightly less time to wait for human data. Mechanism is appealing for sustained executive function maintenance; safety unknown.

  • 50+, brain preservation / mild cognitive decline
    STRONG-CANDIDATE

    per Knoll framework IF research-chem path acceptable AND liver function is clean AND no concurrent MAOI/SSRI. The animal lifespan + tumor-suppression + cognitive-aging-reversal data is most directly relevant to this demographic. The risk/benefit equation tilts toward "try it" in users where DA preservation is mechanistically wanted and short-term hepatotoxicity risk is acceptable vs slow cognitive decline.

  • Anxiety-prone
    WATCH-LIST

    with caution. NE enhancement may amplify anxiety. Start very low (50 mcg or every-other-day) if pursued.

  • High athletic load, tested status
    U

    status (Dylan): no WADA issue. BPAP is not on the prohibited list (not a recognized pharmaceutical). Drug-test cross-reactivity unknown — theoretically should not trigger amphetamine immunoassay, but no validated data. For drug-tested athletes: avoid until tested.

  • Sleep-disordered
    AM

    dosing only. Not a fit if sleep is already fragile.

  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST

    Neurotrophic data (BDNF/GDNF/NGF upregulation in astrocytes) is interesting for TBI recovery context. BPC-157, GHK-Cu, methylene blue, semax-class peptides have stronger direct evidence. BPAP is not first-line.

  • Strength/anabolic-focused
    N

    Not in the muscle-building pathway. Mild drive enhancement only.

▸ Subjective experience (deep)

What few user reports exist describe a clean dopaminergic + slight serotonergic lift over a several-hour window: improved mood, drive enhancement, focus / concentration, no jittery stimulant edge, no obvious comedown, no reported tolerance buildup across repeated doses. Onset ~30-60 min after sublingual or oral administration; peak effect overlaps the rat PK profile (peak plasma 30-60 min); duration roughly 4-6 hours per dose with the half-life suggesting one daily dose covers a workday.

The "cleaner selegiline" subjective framing is what limited reports exist describe — less of the "subtle to imperceptible" character of low-oral selegiline, more of an actually-noticeable mood/drive lift that doesn't feel like a stimulant. Heavy honesty caveat: N is in the dozens at most across all forums, not the hundreds-to-thousands that sustain modafinil's anecdote base. Pattern is suggestive, not validated.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Reported as minimal in animal studies and the limited human anecdotes; mechanism (impulse-coupled, physiologically-gated CAE) predicts low tolerance development by the same logic that applies to low-dose selegiline. Receptor downregulation should be minimal because synaptic concentrations don't reach supraphysiologic levels.
  • Recommended cycle: Knoll's protocol was indefinite. No cycling needed in his framework. A precautionary 5-on/2-off weekly schedule is harmless if desired.
  • Reset protocol: if reset desired, ~2 weeks washout. No long-term receptor or enzyme inhibition like selegiline's 40-day MAO-B regeneration.
▸ Stacking deep dive

Synergistic with

  • bromantane: Different mechanism (bromantane upregulates DA synthesis at TH/AAAD level + raises GSH; BPAP enhances impulse-evoked DA release downstream). Theoretical stack is elegant — BPAP amplifies what bromantane has built. No empirical data.
  • modafinil: Different mechanism (modafinil = DA reuptake inhibition + histamine + orexin; BPAP = TAAR1-mediated impulse-coupled release). Theoretical stack is clean. No empirical data.
  • alcar / DHA / citicoline / NAC: Standard "support what you're enhancing" stack. Mitochondrial + membrane + antioxidant + cholinergic substrates. All neutral-to-additive.
  • semax / adamax / NASA: Different class entirely (peptide BDNF/neurotrophic). No mechanism overlap. Likely safe co-administration; potentially complementary (BPAP enhances release, semax-class enhances neurotrophic signaling that supports the neurons doing the releasing).

Avoid stacking with — IMPORTANT

  • selegiline (any tier): DO NOT STACK. Mechanism overlap (both are CAE-active via TAAR1) + selegiline's MAO-B inhibition layered on top of BPAP's CAE risks unpredictable amplification of dopaminergic/noradrenergic effect. Selegiline's L-amphetamine metabolite + BPAP's NE enhancement could produce hypertensive/agitation events. Pick one or the other. This is the single most important stacking rule for BPAP in Dylan's stack design — choosing BPAP means dropping the planned low-oral selegiline, not adding it.
  • rasagiline, phenelzine, tranylcypromine, isocarboxazid, linezolid: other MAOIs — same logic as selegiline plus more dangerous because non-selective MAO-A inhibition. Contraindicated.
  • Adderall / Vyvanse / Dexedrine / methamphetamine / cocaine: combination of forced-release stimulant + CAE could produce hypertensive crisis or arrhythmia. Avoid.
  • MDMA: serotonin syndrome risk + cardiovascular risk. Contraindicated.
  • SSRIs / SNRIs: theoretical serotonin syndrome risk given BPAP's direct serotonergic enhancement. Probably manageable at low BPAP dose with low-dose SSRI based on selegiline analogy, but no direct data — default to avoid pending Phase 1.
  • Tramadol, meperidine, methadone, DXM: serotonergic opioids/antitussives. Contraindicated.
  • St. John's Wort, 5-HTP, high-dose L-tryptophan: serotonin syndrome risk. Dylan's planned 1 g L-tryptophan pre-bed — at temporal separation from morning BPAP and at this low tryptophan dose, probably safe, but worth flagging if BPAP enters the stack.

Neutral / safe co-administration

  • Caffeine (standard doses)
  • Creatine
  • Magnesium / D3 / K2 / Vitamin C / NAC
  • Theanine / glycine / taurine / beta-alanine
  • Apigenin (mild MAO-A in vitro, but at supplement doses not clinically meaningful given BPAP's lack of MAO inhibition)
  • BPC-157, TB-500, GHK-Cu, peptides generally — different mechanism class
  • Cerebrolysin — neutral
▸ Drug interactions deep dive
  • CYP enzymes: No published human CYP characterization. Rat data shows no MAO involvement in metabolism. CYP2D6/3A4/2B6 likely contribute by analogy to other amino-pentane compounds but not characterized.
  • Anesthetics: Disclose to anesthesiology if surgery is planned. The serotonergic + catecholaminergic activity warrants caution analogous to MAOI precautions even though BPAP is not an MAOI.
  • Sympathomimetics (pseudoephedrine, ephedrine, phenylephrine): theoretical BP elevation risk via additive NE effect. Avoid co-administration in same window.
▸ Pharmacogenomics

The pharmacogenomics of BPAP are not characterized in humans, so this section is mostly inference.

Likely-relevant SNPs based on mechanism

  • TAAR1 variants (rs8192620 and others): TAAR1 is the proximate molecular target. Variants in TAAR1 should plausibly predict response variability, but no direct studies in humans for BPAP. 23andMe v5 chip coverage of TAAR1 SNPs is limited.
  • DAT1 / SLC6A3 VNTR (rs28363170, 9-repeat vs 10-repeat): dopamine transporter is the entry route for BPAP into dopaminergic neurons. Variants affecting transporter density should plausibly affect intracellular BPAP exposure and thus TAAR1 activation. 9-repeat carriers (lower DAT density) may need lower doses.
  • NET1 / SLC6A2 variants: norepinephrine transporter — entry route in noradrenergic neurons. Same logic.
  • SERT / SLC6A4 (5-HTTLPR): serotonin transporter. Same logic for BPAP's serotonergic component.
  • COMT Val158Met (rs4680): PFC DA tone baseline. Met/Met (low COMT, high DA) may have less marginal benefit from a DA-enhancing CAE; Val/Val may benefit more. Same logic as for selegiline.
  • DRD2/ANKK1 Taq1A (rs1800497): A1 carriers (lower D2 density) may be more responsive to DA-enhancing compounds.
  • MAO-A uVNTR + MAO-B intron 13: less directly relevant than for selegiline since BPAP doesn't inhibit MAO at clinical dose, but baseline MAO activity affects ambient DA tone and thus the substrate BPAP is amplifying.

For Dylan specifically (23andMe pending June 2026)

Flag these for review when results land:

  1. rs8192620 (TAAR1) if covered
  2. rs28363170 (DAT1 VNTR) — 9 vs 10 repeat
  3. rs4680 (COMT Val158Met)
  4. rs1800497 (DRD2/ANKK1 Taq1A)
  5. rs6347 (DAT1 SNP, additional DAT1 marker)

These overlap substantially with the selegiline pharmacogenomics flag set — same biological pathway being interrogated with a different drug.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem liquid solution Umbrella Labs $49.99 / 30 mL @ 100 mcg/mL = 3 mg total Medium-high Public-facing US-based vendor; published COA per batch (≥99% LC-MS); ~30-day supply at 100 mcg/day. Well-established research-chem vendor; not Kimera-tier specialized but reasonable.
Research-chem liquid solution Kimera Chems $46.99-$56.99 / 30 mL @ 100 mcg/mL = 3 mg; or 200 mcg/mL = 6 mg High Vendor Dylan is already comfortable with (TAK-653 sourcing). Published COA per batch (≥97% HPLC). 200 mcg/mL option doubles the per-bottle dose but requires precise dropper measurement to avoid over-dose. Likely best path for Dylan.
Research-chem capsules Kimera Chems / Umbrella Labs $45-50 / 60 caps @ 50-100 mcg/cap = 3-6 mg total Medium-high Capsule format avoids dropper-measurement error but introduces content-uniformity risk at sub-mg dosing. COA-essential.
Chinese bulk powder Macklin / Excenen / PGLChem Historical: $500-2500 / 1-5 g Low-medium Powder-form bulk has independent identity verification problem; sub-mg measurement requires analytical balance + diluent prep. Not recommended unless laboratory-grade analytical setup exists.
Compounding pharmacy None known N/A N/A BPAP is not a recognized pharmaceutical, so no licensed compounder will prepare it.
Rx None N/A N/A No approved BPAP product anywhere in the world as of 2026-05-05.

For Dylan: Kimera Chems liquid solution is the clear path if pursued — $50/month at 100 mcg/day = ~$600/year. Vendor familiarity (already comfortable from TAK-653 context), batch COA, ≥97% HPLC purity, dropper-dosed format.

Critical sourcing caveats:

  1. Verify COA matches the lot received — request lot number on bottle and cross-check against the published COA on vendor site
  2. Store cold (2-8°C per Umbrella Labs guidance) and use within reasonable timeframe (PEG400/PG vehicles are stable but the drug itself should not sit at room temp indefinitely)
  3. The liquid is typically dropper-bottle dosed at ~10 mcg/drop (100 mcg/mL × 0.1 mL/drop) — verify dropper calibration before assuming dose; some droppers deliver 0.05 mL/drop = 5 mcg/drop. Test with water + scale.
▸ Biomarkers to track (deep)

Baseline (before starting)

  • Resting BP + orthostatic delta
  • HR resting
  • Liver panel (ALT, AST, GGT) — emphasized given benzofuran class concern
  • Mood self-report (PHQ-9 or 0-10 scale)
  • Sleep onset latency + total sleep time (Oura)
  • Libido / drive baseline
  • 23andMe SNP review (DAT1, COMT, DRD2, TAAR1 if covered) — Dylan's pending June 2026

During use

  • Resting BP weekly first month, monthly thereafter
  • HR weekly first month, monthly thereafter
  • ALT/AST at 4 weeks, 12 weeks, then every 6 months — non-negotiable given benzofuran class concern
  • Mood + drive + focus self-report weekly first month
  • Sleep metrics ongoing
  • Watch for: headache pattern, BP elevation, vivid dreams, anxiety amplification, GI symptoms

Post-cycle (if discontinuing)

  • ~2 week observation for baseline return
  • Liver panel at 4-8 weeks post-discontinuation if any concern arose during use
▸ Controversies / open debates Live debate

"Cleaner selegiline" — accurate framing or marketing?

Mechanistically accurate. BPAP is closer to a "pure CAE" than selegiline is — the framework Knoll explicitly built. Selegiline's CAE activity is layered on top of permanent MAO-B inhibition + the L-amphetamine/L-methamphetamine metabolite contribution; BPAP gives you the CAE without those secondary effects. The framing is real, not just marketing.

But: "cleaner" doesn't mean "better." MAO-B inhibition is part of why selegiline preserves DA over decades — that mechanism is GONE from BPAP. The trade is: BPAP gives broader monoamine coverage (also serotonin, which selegiline doesn't enhance) + higher CAE potency + cleaner secondary mechanism profile, in exchange for losing the irreversible enzyme inhibition that anchors selegiline's evidence base. Whether that trade is net-positive depends on what you wanted from selegiline in the first place.

The Knoll lab dominance problem

Real and worth flagging. Almost all of the "definitive" BPAP data — the 130× potency claim, the bell-curve dose-response, the cognitive-aging-reversal in 18-month-old rats, the lifespan extension, the tumor suppression — comes from Knoll's lab in Budapest at Semmelweis. Independent replication outside the Knoll/Miklya group is sparse.

The 2025 TAAR1 mechanism work (Springer Neurochem Res) is independent and confirms the TAAR1 pathway, which strengthens the mechanistic claim. The Yasar et al. 2008 antidepressant model work (PMID 18243357) is also independent. So the picture is not "single-lab-only" — but the most striking efficacy claims (lifespan, tumor suppression, 130× potency) do still rest on the Knoll lab as primary source, and Knoll died in 2018 without seeing his framework either validated or refuted in humans.

Why has BPAP never made it to standard human clinical development?

This is the most important unanswered question. Possible explanations:

  1. Patent expiration / commercial unviability — Knoll's compound aged out of patent before any pharma company committed to development. The Fujimoto Phase 2 effort suggests at least one company tried, but no public Phase 2 results means it likely stalled at development/toxicology rather than producing a cleanly negative readout.
  2. Difficult patient population — selegiline already exists for Parkinson's, and the BPAP development case for adjunct/replacement is incremental at best.
  3. Bell-curve dose-response is hard to clinically translate — narrow optimal-dose window across heterogeneous human population is a regulatory headache.
  4. Hepatotoxicity surfaced in unpublished pre-clinical or Phase 1? — speculative, but the benzofuran scaffold concern raises this possibility. If true, this would be the worst-case explanation for the development silence.

The honest answer is: we don't know why. The absence of human clinical activity is the central red flag.

Sub-mg dosing accuracy in the research-chem ecosystem

Real concern, not paranoia. A 100 mcg dose is 1/50th of a 5 mg selegiline tablet. If a vendor's stated 100 mcg/mL is actually 250 mcg/mL (e.g., from a powder weighing error during reconstitution), every dose is 2.5× the intended. If the substance is misidentified as a structural analog with different potency (e.g., a cathinone-class amphetamine variant), the consequences could be acute. The Kimera-class vendor with per-batch HPLC COA is the realistic minimum bar; even there, content uniformity verification on receipt would not be unreasonable for serious chronic use.

"Different drug" vs "selegiline successor" framing

The question of whether BPAP is a "cleaner selegiline" or a "fundamentally different drug" matters because it determines what evidence transfer is legitimate. My read: the CAE/MAE/TAAR1 mechanism IS shared with selegiline at the secondary-mechanism level. So selegiline's safety profile at the CAE-effect-only dose tier (low oral) DOES partially translate to BPAP. But BPAP's unique features (no MAO inhibition, broader monoamine including serotonin, benzofuran scaffold, ~130× higher CAE potency) mean meaningful aspects do NOT transfer — particularly the safety database. Default to treating BPAP as a different drug in the same family rather than a "better selegiline."

▸ Verdict change log
  • 2026-05-05 — Initial verdict: WATCH-LIST, LOW confidence. The mechanistic case for BPAP as a cleaner selegiline successor is real and the animal data is impressive, but zero published human RCTs + opaque Fujimoto Phase 2 status + research-chem-only sourcing + benzofuran-class liver concern + sub-mg dosing accuracy demands push this out of "stack candidate today" territory. For Dylan: do NOT add to V5 launch stack; revisit as a possible selegiline replacement after V5 is steady-state and Dylan has ~6 months of low-oral selegiline experience as comparison baseline.
▸ Open questions / gaps Open

  1. Does BPAP genuinely replace selegiline for Dylan? The honest framing: theoretically yes per mechanism + Knoll animal data, but human translation absent. Replacing a drug with 40+ years of human safety data + Rx access + $25/month cost with a research-chem at $50+/month + zero human safety data is not a defensible swap UNTIL one of the following changes: Phase 1 lands, Fujimoto Phase 2 reports positive, or a substantial healthy-volunteer biohacker dataset accumulates with structured outcome reporting. For now, low-oral selegiline is the right choice; BPAP is the right thing to watch.

  2. What is the actual status of FPFS-1169 / Fujimoto Phase 2? The single most important data gap. If a clinical trial registry entry exists, it would change the verdict-confidence tier. Periodic checking of Patsnap Synapse + clinicaltrials.gov + clinicaltrialsregister.eu is the right monitoring approach.

  3. Hepatotoxicity in long-term human use — does the benzofuran class concern apply? The structural analogy to benzbromarone/benzarone is unsettling. Need a human chronic-use safety database before this can be retired as a concern.

  4. Sub-mg dosing accuracy — is COA + dropper-dosed liquid sufficient? Probably yes IF vendor analytics are real and dropper is calibrated. But the failure mode is undetected and potentially serious.

  5. TAAR1 pharmacogenomics in humans — does response variability follow predicted patterns? Would let users predict their likely response by genotype. Would also help establish the biological case if response correlated with TAAR1 genotype.

  6. Is the bimodal dose-response real in humans? Confirmed in rats. Translation uncertain. If a user titrates up and stops feeling effect, the right interpretation may be "passed the specific peak," not "tolerance" — but this is speculative without dose-titration data.

  7. Combination with bromantane — theoretical synergy, no data. Both Knoll-era / Russian-origin Eastern-bloc compounds with CAE-related mechanism. Stack remains unstudied. Default to caution + sequential rather than simultaneous initiation if pursued.

▸ Sources (full, with our context)
Back to compact view